00896nas a2200385   4500000000100000008004100001260001300042653002500055653001000080653000900090653002200099653001200121653001100133653001200144653003100156653001100187653000900198653001100207653001200218653000900230653001200239653000900251653001600260653002500276653001500301653000900316653001700325100001100342700001600353700001200369245009700381300001100478490000700489022001400496       1972                            d  c1972 May10aAdministration, Oral10aAdult10aAged10aAniline Compounds10aAnimals10aBiopsy10aDapsone10aDrug Resistance, Microbial10aFemale10aFoot10aHumans10aleprosy10aMale10aMethods10aMice10aMiddle Aged10aMycobacterium leprae10aPhenazines10aSkin10aTime Factors1 aLevy L1 aShepard C C1 aFasal P00aClofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae.  a315-210 v21  a0002-9637